8-K: SANUWAVE Restates Financials Over Tax Liability

SANUWAVE Health, Inc. announced it will restate previously issued financial statements due to an identified historical state sales and use tax liability.

Summary

• SANUWAVE Health, Inc. (SNWV) has determined that its previously issued unaudited condensed consolidated financial statements for various periods in 2024 and 2025, and its audited consolidated financial statements for the year ended December 31, 2024, should no longer be relied upon.
• This non-reliance stems from the identification of a historical state sales and use tax liability, discovered after a third-party nexus study, which the company is required to collect and remit.
• The company plans to restate its consolidated financial statements for the year ended December 31, 2024, and include restated unaudited financial information for other affected periods in its upcoming Annual Report on Form 10-K for the year ended December 31, 2025.
• The expected financial impact includes an aggregate increase in reported liabilities of between $4.9 million to $5.2 million as of December 31, 2025.
• Additionally, the company anticipates an aggregate increase in previously reported expense of between $1.6 million to $1.8 million for the year ended December 31, 2024, and between $1.7 million to $1.9 million for the year ended December 31, 2025, both including taxes, interest, and penalties.
• Management is evaluating whether this issue will lead to the identification of additional material weaknesses in the company's internal control over financial reporting, with conclusions to be included in the 2025 Form 10-K.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a significantly negative event due to the non-reliance on past financials, the material financial impact of the restatement, and the potential for identified material weaknesses in internal controls, which collectively undermine investor confidence.

Negatives

• Previously issued unaudited and audited financial statements for multiple periods in 2024 and 2025 can no longer be relied upon.
• The company will incur an aggregate increase in reported liabilities of between $4.9 million to $5.2 million as of December 31, 2025.
• An aggregate increase in previously reported expense of between $1.6 million to $1.8 million (including taxes, interest, and penalties) for the year ended December 31, 2024.
• An aggregate increase in reported expense of between $1.7 million to $1.9 million (including taxes, interest, and penalties) for the year ended December 31, 2025.
• The company is evaluating whether the matter will result in the identification of additional material weaknesses in its internal control over financial reporting.

Risks

• Future financial results may differ materially from current expectations.
• Potential delays in the filing of the 2025 Form 10-K or other required periodic reports.
• The timing and results of the company's review of the effectiveness of internal control over financial reporting and related disclosure controls and procedures.
• Whether a restatement or correction of financial results will be required for other accounting issues.
• Adverse effects on the company related to the disclosures made in this report.

Future Outlook

The company plans to restate its consolidated financial statements for the year ended December 31, 2024, and include restated unaudited financial information for other affected periods in its Annual Report on Form 10-K for the year ended December 31, 2025, which it expects to timely file. Management is also evaluating whether this issue will lead to the identification of additional material weaknesses in internal control over financial reporting, with conclusions to be included in the 2025 Form 10-K.

Management Comments

• "Management used this third party report and identified that the Company had a historical state sales and use tax liability related to prior periods."
• "The Company is required and subject to collect and remit sales and use tax in state and local jurisdictions where it has economic and physical nexus."
• "Managements conclusions regarding the impacts of the matter discussed above on the Companys internal control over financial reporting will be included in the 2025 Form 10-K, which the Company expects to timely file with the SEC."

Industry Context

StockSavvy.ai notes that financial restatements, particularly those stemming from tax compliance issues and potential internal control weaknesses, can erode investor confidence and often lead to increased scrutiny from regulators and auditors. This event highlights the critical importance of robust internal controls and thorough tax nexus studies for companies operating across multiple jurisdictions.

Comparison to Industry Standards

• StockSavvy.ai notes that while specific comparable companies are not mentioned in the filing, financial restatements due to identified tax liabilities are generally viewed negatively across all industries.
• Companies like Enron or WorldCom faced severe consequences for financial misstatements, though the scale and nature of SANUWAVE's issue appear to be different. However, even smaller restatements can signal underlying control deficiencies, which are below industry best practices for financial reporting integrity.

Stakeholder Impact

• Shareholders will face uncertainty regarding the accuracy of past financial performance and potential negative impact on stock price due to restatement and control weaknesses.
• Investors may lose confidence in the company's financial reporting and internal controls.
• Regulatory Authorities (SEC) will scrutinize the restatement and the company's remediation efforts regarding internal controls.
• Auditors (Baker Tilly and Marcum LLP) will have their past work under review and are involved in the discussions regarding the non-reliance.

Next Steps

• Restate consolidated financial statements for the year ended December 31, 2024.
• Include restated unaudited financial information for Q1, Q2, Q3 2024 and Q1, Q2, Q3 2025 in the 2025 Form 10-K.
• Evaluate whether the matter will result in the identification of additional material weaknesses in internal control over financial reporting.
• File the 2025 Form 10-K with the SEC, including management's conclusions on internal controls.

Key Dates

Recommendation

The non-reliance on previously issued financial statements, coupled with a material restatement of liabilities and expenses, signals significant financial reporting deficiencies and potential internal control weaknesses. This erodes investor confidence and introduces substantial uncertainty regarding the company's true financial health and operational integrity. The potential for further delays or additional accounting issues, as noted in the risks, further supports a 'sell' recommendation until the company demonstrates robust remediation and consistent, reliable financial reporting.

Keywords

SANUWAVE Health, SNWV, SEC filing, 8-K, financial restatement, sales and use tax, tax liability, internal controls, material weakness, financial reporting, Nasdaq